Cartalax peptide is a synthetic tripeptide (Ala-Glu-Asp) developed as a cartilage-specific bioregulator to support joint and tissue health.  It functions at the cellular and genetic level to promote cartilage regeneration and protect against degeneration. 
Cartilage Repair & Regeneration: Cartalax stimulates chondrocytes (cartilage cells) to increase production of collagen and proteoglycans, essential structural components that maintain cartilage elasticity and cushioning. 
Anti-Inflammatory Effects: It reduces inflammation by inhibiting matrix metalloproteinases (MMP-9) and pro-inflammatory cytokines, helping to prevent cartilage breakdown. 
Anti-Aging & Cellular Protection: Cartalax modulates aging markers such as p53, p16, and p21, while boosting SIRT-6, a longevity-associated protein, to slow cellular senescence and enhance tissue resilience. 
Stress Resilience & Growth Signaling: It enhances IGF-1 levels and may support TERT and NF-κB pathways, promoting cell repair, growth, and stress adaptation. 
Joint Mobility & Recovery: By improving cartilage quality and reducing stiffness, Cartalax supports joint function, making it beneficial for osteoarthritis management, post-injury recovery, and athletic performance. 
Systemic Tissue Support: Beyond joints, Cartalax shows potential in improving skin fibroblast activity, nephroprotection, and bone metabolism via effects on thyroid C cells. 
While primarily studied in Russia and Eastern Europe, Cartalax is considered experimental in most Western countries and is not FDA-approved. It is typically used in short 10–20 day cycles via oral capsules or injectables, with a favorable safety profile in short-term use.